Occam Recruits Sales and Operations Leader to the Board of Geron
In March 2019, Occam Global recruited Dawn C. Bir to the Board of Geron Corporation, a public commercial-stage oncology biotech. Bir also serves on the Board of Soleno Therapeutics and was the Chief Commercial Officer at Reata Pharmaceuticals from September 2016 until Biogen’s $7.3B acquisition of Reata in 2023. Prior to her time at Reata, she held several key leadership positions at Pharmacyclics, McKesson, Genentech, and Bristol-Myers Squibb, demonstrating a strong track record in sales, operations, and team development across various therapeutic areas.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.